{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T16:12:37Z","timestamp":1781194357775,"version":"3.54.1"},"update-to":[{"DOI":"10.1371\/journal.pntd.0011500","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T00:00:00Z","timestamp":1713830400000}}],"reference-count":45,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2024,4,11]],"date-time":"2024-04-11T00:00:00Z","timestamp":1712793600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010767","name":"Innovative Medicines Initiative","doi-asserted-by":"publisher","award":["grant agreement EBOVAC1 (grant nr. 115854), EBOVAC2 (grant nr. 115861) and EBOVAC3 (grant nr.800176)"],"award-info":[{"award-number":["grant agreement EBOVAC1 (grant nr. 115854), EBOVAC2 (grant nr. 115861) and EBOVAC3 (grant nr.800176)"]}],"id":[{"id":"10.13039\/501100010767","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosntds.org"],"crossmark-restriction":false},"short-container-title":["PLoS Negl Trop Dis"],"abstract":"\n Background<\/jats:title>\n The exposure to parasites may influence the immune response to vaccines in endemic African countries. In this study, we aimed to assess the association between helminth exposure to the most prevalent parasitic infections, schistosomiasis, soil transmitted helminths infection and filariasis, and the Ebola virus glycoprotein (EBOV GP) antibody concentration in response to vaccination with the Ad26.ZEBOV, MVA-BN-Filo vaccine regimen in African and European participants using samples obtained from three international clinical trials.<\/jats:p>\n <\/jats:sec>\n \n Methods\/Principal findings<\/jats:title>\n \n We conducted a study in a subset of participants in the EBL2001, EBL2002 and EBL3001 clinical trials that evaluated the Ad26.ZEBOV, MVA-BN-Filo vaccine regimen against EVD in children, adolescents and adults from the United Kingdom, France, Burkina Faso, Cote d\u2019Ivoire, Kenya, Uganda and Sierra Leone. Immune markers of helminth exposure at baseline were evaluated by ELISA with three commercial kits which detect IgG antibodies against schistosome, filarial and\n Strongyloides<\/jats:italic>\n antigens. Luminex technology was used to measure inflammatory and activation markers, and Th1\/Th2\/Th17 cytokines at baseline. The association between binding IgG antibodies specific to EBOV GP (measured on day 21 post-dose 2 and on Day 365 after the first dose respectively), and helminth exposure at baseline was evaluated using a multivariable linear regression model adjusted for age and study group.\n <\/jats:p>\n \n Seventy-eight (21.3%) of the 367 participants included in the study had at least one helminth positive ELISA test at baseline, with differences of prevalence between studies and an increased prevalence with age. The most frequently detected antibodies were those to\n Schistosoma mansoni<\/jats:italic>\n (10.9%), followed by\n Acanthocheilonema viteae<\/jats:italic>\n (9%) and then\n Strongyloides ratti<\/jats:italic>\n (7.9%). Among the 41 immunological analytes tested, five were significantly (p < .003) lower in participants with at least one positive helminth ELISA test result: CCL2\/MCP1, FGFbasic, IL-7, IL-13 and CCL11\/Eotaxin compared to participants with negative helminth ELISA tests. No significant association was found with EBOV-GP specific antibody concentration at 21 days post-dose 2, or at 365 days post-dose 1, adjusted for age group, study, and the presence of any helminth antibodies at baseline.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions\/Significance<\/jats:title>\n No clear association was found between immune markers of helminth exposure as measured by ELISA and post-vaccination response to the Ebola Ad26.ZEBOV\/ MVA-BN-Filo vaccine regimen.<\/jats:p>\n <\/jats:sec>\n \n Trial registration<\/jats:title>\n \n NCT02416453<\/jats:ext-link>\n ,\n NCT02564523<\/jats:ext-link>\n ,\n NCT02509494<\/jats:ext-link>\n . ClinicalTrials.gov.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1371\/journal.pntd.0011500","type":"journal-article","created":{"date-parts":[[2024,4,11]],"date-time":"2024-04-11T16:19:58Z","timestamp":1712852398000},"page":"e0011500","update-policy":"https:\/\/doi.org\/10.1371\/journal.pntd.corrections_policy","source":"Crossref","is-referenced-by-count":5,"title":["Helminth exposure and immune response to the two-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccine regimen"],"prefix":"10.1371","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8114-1240","authenticated-orcid":true,"given":"Houreratou","family":"Barry","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edouard","family":"Lhomme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"Sur\u00e9naud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moumini","family":"Nouctara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viki","family":"Bockstal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Innocent","family":"Valea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serge","family":"Somda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Halidou","family":"Tinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Meda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Greenwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5235-3962","authenticated-orcid":true,"given":"Rodolphe","family":"Thi\u00e9baut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Lacabaratz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2024,4,11]]},"reference":[{"issue":"10174","key":"pntd.0011500.ref001","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/S0140-6736(18)33132-5","article-title":"Ebola virus disease","volume":"393","author":"D Malvy","year":"2019","journal-title":"Lancet"},{"key":"pntd.0011500.ref002","article-title":"WHO prequalifies Ebola vaccine, paving the way for its use in high-risk countries.","author":"World Health Organization"},{"key":"pntd.0011500.ref003","article-title":"Strategic Advisory Group of Experts (SAGE) on immunization interim recommendations on vaccination against Ebola Virus Disease (EVD)","author":"World Health Organization","year":"2019"},{"key":"pntd.0011500.ref004","unstructured":"Vaccine against Ebola: Commission grants new market authorizations. Press Release 11 November 2019 [cited 2021 Mar 25]. Available from: https:\/\/ec.europa.eu\/commission\/presscorner\/detail\/en\/IP_20_1248"},{"key":"pntd.0011500.ref005","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S1473-3099(20)30476-X","article-title":"Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (Ebovac2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial","volume":"21","author":"AJ Pollard","year":"2021","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"pntd.0011500.ref006","doi-asserted-by":"crossref","first-page":"e1003865","DOI":"10.1371\/journal.pmed.1003865","article-title":"Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in children and adolescents in Africa: A randomised, placebo-controlled, multicentre Phase II clinical trial.","volume":"19","author":"Z Anywaine","year":"2022","journal-title":"PLoS Med"},{"issue":"10","key":"pntd.0011500.ref007","doi-asserted-by":"crossref","first-page":"e1003813","DOI":"10.1371\/journal.pmed.1003813","article-title":"Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in healthy and HIV-infected adults: A randomised, placebo-controlled Phase II clinical trial in Africa.","volume":"18","author":"H Barry","year":"2021","journal-title":"PLoS Med"},{"issue":"1","key":"pntd.0011500.ref008","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S1473-3099(21)00125-0","article-title":"Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial.","volume":"22","author":"D Ishola","year":"2022","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"pntd.0011500.ref009","first-page":"110","article-title":"Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in children in Sierra Leone: a randomised, double-blind, controlled trial.","volume":"22","author":"MO Afolabi","year":"2021"},{"issue":"1","key":"pntd.0011500.ref010","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1093\/infdis\/jiz071","article-title":"Safety and immunogenicity of a 2-dose heterologous vaccine regimen with ad26. Zebov and mva-bn-filo ebola vaccines: 12-month data from a phase 1 randomized clinical trial in nairobi, kenya","volume":"220","author":"G Mutua","year":"2019","journal-title":"J Infect Dis"},{"issue":"15","key":"pntd.0011500.ref011","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1001\/jama.2016.4218","article-title":"Safety and immunogenicity of novel adenovirus type 26\u2013 and modified vaccinia ankara\u2013vectored ebola vaccines: a randomized clinical trial","volume":"315","author":"ID Milligan","year":"2016","journal-title":"JAMA"},{"issue":"1","key":"pntd.0011500.ref012","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1093\/infdis\/jiz070","article-title":"Safety and immunogenicity of a 2-dose heterologous vaccination regimen with ad26. Zebov and mva-bn-filo ebola vaccines: 12-month data from a phase 1 randomized clinical trial in uganda and tanzania","volume":"220","author":"Z Anywaine","year":"2019","journal-title":"J Infect Dis"},{"issue":"18","key":"pntd.0011500.ref013","doi-asserted-by":"crossref","first-page":"e00579","DOI":"10.1128\/JVI.00579-19","article-title":"Dynamics of the humoral immune response to a prime-boost ebola vaccine: quantification and sources of variation","volume":"93","author":"C Pasin","year":"2019","journal-title":"J Virol"},{"issue":"7","key":"pntd.0011500.ref014","doi-asserted-by":"crossref","first-page":"e0270968","DOI":"10.1371\/journal.pone.0270968","article-title":"Prevalence of malaria and helminth infections in rural communities in northern Sierra Leone, a baseline study to inform Ebola vaccine study protocols","volume":"17","author":"F Baiden","year":"2022","journal-title":"PLoS One"},{"issue":"4","key":"pntd.0011500.ref015","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1086\/515661","article-title":"Impaired tetanus-specific cellular and humoral responses following tetanus vaccination in human onchocerciasis: a possible role for interleukin-10","volume":"178","author":"PJ Cooper","year":"1998","journal-title":"J INFECT DIS J Infect Dis"},{"issue":"1","key":"pntd.0011500.ref016","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1093\/infdis\/173.1.269","article-title":"Impairment of tetanus toxoid-specific thl-like immune responses in humans infected with schistosoma mansoni","volume":"173","author":"EA Sabin","year":"1996","journal-title":"J Infect Dis"},{"issue":"7","key":"pntd.0011500.ref017","doi-asserted-by":"crossref","first-page":"e1007182","DOI":"10.1371\/journal.ppat.1007182","article-title":"Chronic schistosomiasis suppresses HIV-specific responses to DNA-MVA and MVA-gp140 Env vaccine regimens despite antihelminthic treatment and increases helminth-associated pathology in a mouse model","volume":"14","author":"GA Dzhivhuho","year":"2018","journal-title":"PLoS Pathog"},{"issue":"3","key":"pntd.0011500.ref018","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1128\/IAI.69.3.1574-1580.2001","article-title":"Human infection with ascaris lumbricoides is associated with suppression of the interleukin-2 response to recombinant cholera toxin b subunit following vaccination with the live oral cholera vaccine CVD 103-","volume":"69","author":"PJ Cooper","year":"2001","journal-title":"HgR. Infect Immun"},{"issue":"6","key":"pntd.0011500.ref019","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.pt.2008.02.009","article-title":"Chronic parasite infections cause immune changes that could affect successful vaccination","volume":"24","author":"G Borkow","journal-title":"Trends Parasitol"},{"issue":"7","key":"pntd.0011500.ref020","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1089\/aid.2015.0274","article-title":"Effect of schistosoma mansoni infection on innate and hiv-1-specific t-cell immune responses in hiv-1-infected ugandan fisher folk","volume":"32","author":"AE Obuku","year":"2016","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"5","key":"pntd.0011500.ref021","first-page":"404","article-title":"Cofactors that may influence vaccine responses: Curr Opin HIV AIDS","volume":"5","author":"G. De Bruyn","year":"2010"},{"issue":"1","key":"pntd.0011500.ref022","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s12865-023-00554-3","article-title":"HIV specific Th1 responses are altered in Ugandans with schistosoma mansoni coinfection","volume":"24","author":"AE Obuku","year":"2023","journal-title":"BMC Immunol"},{"issue":"7","key":"pntd.0011500.ref023","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.1172\/JCI75429","article-title":"Immune activation alters cellular and humoral responses to yellow fever 17D vaccine","volume":"124","author":"E Muyanja","year":"2014","journal-title":"J Clin Invest"},{"issue":"10","key":"pntd.0011500.ref024","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1097\/QAD.0000000000001821","article-title":"Circulating inflammatory monocytes contribute to impaired influenza vaccine responses in HIV-infected participants","volume":"32","author":"VK George","year":"2018","journal-title":"AIDS"},{"issue":"8","key":"pntd.0011500.ref025","doi-asserted-by":"crossref","first-page":"e412","DOI":"10.1371\/journal.pntd.0000412","article-title":"Neglected tropical diseases in sub-saharan africa: review of their prevalence, distribution, and disease burden","volume":"3","author":"PJ Hotez","year":"2009","journal-title":"PLoS Negl Trop Dis"},{"issue":"1","key":"pntd.0011500.ref026","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/S1473-3099(14)71004-7","article-title":"Spatial and temporal distribution of soil-transmitted helminth infection in sub-Saharan Africa: a systematic review and geostatistical meta-analysis","volume":"15","author":"DA Karagiannis-Voules","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"pntd.0011500.ref027","doi-asserted-by":"crossref","first-page":"7658594","DOI":"10.1155\/2019\/7658594","article-title":"Prevalence, intensity of soil-transmitted helminths, and factors associated with infection: importance in control program with ivermectin and albendazole in eastern c\u00f4te d\u2019ivoire","volume":"2019","author":"A Loukouri","year":"2019","journal-title":"J Trop Med"},{"issue":"1","key":"pntd.0011500.ref028","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2471\/BLT.15.161885","article-title":"Schistosomiasis in school-age children in Burkina Faso after a decade of preventive chemotherapy","volume":"94","author":"H Ouedraogo","year":"2016","journal-title":"Bull World Health Organ"},{"key":"pntd.0011500.ref029","doi-asserted-by":"crossref","first-page":"105381","DOI":"10.1016\/j.actatropica.2020.105381","article-title":"Antibody response to Schistosoma haematobium and other helminth species in malaria-exposed populations from Burkina Faso","volume":"205","author":"VD Mangano","year":"2020","journal-title":"Acta Trop"},{"key":"pntd.0011500.ref030","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/1756-3305-7-125","article-title":"Schistosoma haematobium hotspots in south Nyanza, western Kenya: prevalence, distribution and co-endemicity with Schistosoma mansoni and soil-transmitted helminths","volume":"7","author":"HC Sang","year":"2014","journal-title":"Parasit Vectors"},{"issue":"9","key":"pntd.0011500.ref031","doi-asserted-by":"crossref","first-page":"e0005872","DOI":"10.1371\/journal.pntd.0005872","article-title":"Spatial distribution and risk factors of Schistosoma haematobium and hookworm infections among schoolchildren in Kwale, Kenya","volume":"11","author":"EA Chadeka","year":"2017","journal-title":"PLoS Negl Trop DisSep 1"},{"issue":"8","key":"pntd.0011500.ref032","doi-asserted-by":"crossref","first-page":"e0007617","DOI":"10.1371\/journal.pntd.0007617","article-title":"The prevalence of schistosomiasis in Uganda: A nationally representative population estimate to inform control programs and water and sanitation interventions.","volume":"13","author":"NG Exum","year":"2019","journal-title":"PLoS Negl Trop Dis"},{"key":"pntd.0011500.ref033","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fpubh.2019.00001","article-title":"Schistosomiasis in school age children in sierra leone after 6 years of mass drug administration with praziquantel.","volume":"7","author":"YM Bah","year":"2019","journal-title":"Front Public Health"},{"issue":"4","key":"pntd.0011500.ref034","doi-asserted-by":"crossref","first-page":"260","DOI":"10.3855\/jidc.1688","article-title":"Anemia, leukocytosis and eosinophilia in a resource-poor population with helmintho-ectoparasitic coinfection","volume":"5","author":"D Pilger","year":"2011","journal-title":"J Infect Dev Ctries"},{"issue":"4","key":"pntd.0011500.ref035","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1586\/erv.10.16","article-title":"Suppression of vaccine responses by malaria: insignificant or overlooked?","volume":"9","author":"AJ Cunnington","year":"2010","journal-title":"Expert Rev Vaccines"},{"issue":"2","key":"pntd.0011500.ref036","doi-asserted-by":"crossref","first-page":"e00084","DOI":"10.1128\/CMR.00084-18","article-title":"Factors that influence the immune response to vaccination","volume":"32","author":"P Zimmermann","year":"2019","journal-title":"Clin Microbiol Rev"},{"issue":"8078","key":"pntd.0011500.ref037","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1016\/S0140-6736(78)92403-0","article-title":"Impairment of the immune response to vaccination after acute malaria","volume":"1","author":"WA Williamson","year":"1978","journal-title":"Lancet"},{"issue":"9","key":"pntd.0011500.ref038","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1093\/cid\/ciac209","article-title":"Asymptomatic Malaria Infection and the Immune Response to the 2-Dose Ad26.ZEBOV, MVA-BN-Filo Ebola Vaccine Regimen in Adults and Children","volume":"75","author":"EBOVAC-Salone Malaria Infection (MALI) Sub-Study Team","year":"2022","journal-title":"Clin Infect Dis"},{"issue":"13","key":"pntd.0011500.ref039","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1097\/00002030-199611000-00012","article-title":"Immunological activation markers in the serum of African and European HIV-seropositive and seronegative individuals","volume":"10","author":"G Rizzardini","year":"1996","journal-title":"AIDS"},{"issue":"19","key":"pntd.0011500.ref040","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1001\/jama.1987.03390190095027","article-title":"Serologic and immunologic studies in patients with AIDS in North America and Africa. The potential role of infectious agents as cofactors in Human Immunodeficiency Virus infection","volume":"257","author":"TC Quinn","year":"1987","journal-title":"JAMA"},{"issue":"16","key":"pntd.0011500.ref041","doi-asserted-by":"crossref","first-page":"6718","DOI":"10.1073\/pnas.0901983106","article-title":"Microbial translocation, the innate cytokine response, and HIV-1 disease progression in Africa","volume":"106","author":"AD Redd","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"pntd.0011500.ref042","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1586\/14760584.2014.885841","article-title":"Ebola virus vaccines: An overview of current approaches.","volume":"13","author":"A Marzi","year":"2014","journal-title":"Expert Rev. Vaccines"},{"key":"pntd.0011500.ref043","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1016\/S0140-6736(02)08353-8","article-title":"BCG-induced increase in interferon-gamma response to mycobacterial antigens and efficacy of BCG vaccination in Malawi and the UK: two randomized controlled studies","volume":"359","author":"FB Gillian","year":"2002","journal-title":"Lancet"},{"key":"pntd.0011500.ref044","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/S1473-3099(16)30023-8","article-title":"The effect of azithromycin on the immunogenicity of oral poliovirus vaccine: a double-blind randomized placebo-controlled trial in seronegative Indian infants.","volume":"16","author":"G Nicholas C","year":"2016","journal-title":"Lancet infect Dis"},{"issue":"1","key":"pntd.0011500.ref045","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41541-023-00627-9","article-title":"The immunological interplay between vaccination and the intestinal microbiota.","volume":"8","author":"P. Zimmermann","year":"2023","journal-title":"NPJ Vaccines"}],"updated-by":[{"DOI":"10.1371\/journal.pntd.0011500","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T00:00:00Z","timestamp":1713830400000}}],"container-title":["PLOS Neglected Tropical Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0011500","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T13:48:26Z","timestamp":1713880106000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0011500"}},"subtitle":[],"editor":[{"given":"Eva","family":"Clark","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,4,11]]},"references-count":45,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,4,11]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pntd.0011500","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2023.07.05.23292287","asserted-by":"object"}]},"ISSN":["1935-2735"],"issn-type":[{"value":"1935-2735","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,11]]}}}